Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Consolidated Net Income: 2010-2024

Historic Consolidated Net Income for Whitehawk Therapeutics (WHWK) over the last 13 years, with Dec 2024 value amounting to -$63.7 million.

  • Whitehawk Therapeutics' Consolidated Net Income fell 41.06% to -$17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.2 million, marking a year-over-year decrease of 67.25%. This contributed to the annual value of -$63.7 million for FY2024, which is 3.15% up from last year.
  • As of FY2024, Whitehawk Therapeutics' Consolidated Net Income stood at -$63.7 million, which was up 3.15% from -$65.8 million recorded in FY2023.
  • Whitehawk Therapeutics' 5-year Consolidated Net Income high stood at -$3.5 million for FY2020, and its period low was -$110.1 million during FY2021.
  • Its 3-year average for Consolidated Net Income is -$63.3 million, with a median of -$63.7 million in 2024.
  • In the last 5 years, Whitehawk Therapeutics' Consolidated Net Income spiked by 85.15% in 2020 and then plummeted by 3,065.32% in 2021.
  • Yearly analysis of 5 years shows Whitehawk Therapeutics' Consolidated Net Income stood at -$3.5 million in 2020, then plummeted by 3,065.32% to -$110.1 million in 2021, then spiked by 45.03% to -$60.5 million in 2022, then dropped by 8.68% to -$65.8 million in 2023, then climbed by 3.15% to -$63.7 million in 2024.